Stockreport

Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF FABP5 platform under exclusive license to Artelo Biosciences NCI support provides further validation of next-generation target for cancer therapeutics LA JOLLA, Calif. [Read more]